The pharmaceutical laboratory closes 2023 with a turnover of 356 million euros. Cantabria Labs is growing by 20% compared to last year, and the good results obtained in 2023 are helping it to maintain its plans to achieve a turnover of 500 million euros by 2027.
As the company explained in the press release, by 2023, the Spanish pharmaceutical laboratory will have a direct presence in more than 85 countries and its own subsidiaries in eight of them. In this document, the company shows its commitment to innovation and invests 12% of its turnover in its R&D&I strategy, and in the previous year it exported 56% of its production abroad. The company has not only grown in turnover, it has also helped it to increase its workforce: in the last five years, the pharmaceutical laboratory has gone from 671 employees to more than 1,000 people, which means a growth of more than 50%.
Susana Rodríguez, CEO and Managing Director of Cantabria Labs, has specified and provided more details about the laboratories' expansion strategy: "only by being global can we fulfil our purpose of improving people's quality of life through science. Game-changing solutions in our specialities: dermatology, immunology, photobiology, nutrition... can emerge anywhere in the world. Our priorities for 2024 will continue to include international growth, commercial excellence and increasing our innovation advantage in our product portfolio."
In 2023, Cantabria Labs reached a very important milestone for the company: its entry into the North American market with the help of entrepreneur and actress Sofía Vergara through the launch of Toty, a range of cosmetic products developed clinically and manufactured exclusively by Cantabria Labs at its La Concha centre in Cantabria.